期刊文献+

盐酸纳曲酮多囊脂质体的处方及制备工艺研究 被引量:1

Formulation and preparation technology of naltrexone hydrochloride multivesicular liposomes
下载PDF
导出
摘要 目的:制备盐酸纳曲酮多囊脂质体(DepoNTX),并考察其理化性质。方法:采用复乳法制备DepoNTX;RP-HPLC法测定含量、包封率;以包封率为指标,单因素及正交试验筛选、优化工艺和处方;光学显微镜下观察多囊脂质体形态、用库尔特计数仪测定其粒径和粒度分布。结果:制备的最佳条件是卵磷脂/胆固醇为1:1(摩尔比),形成复乳的振荡时间为10s,L-赖氨酸的浓度为40mmol·L-1,初乳和第二水相的体积比为1:2.5。粒径范围为5~50μm,平均粒径为12.4μm,包封率为44.5%。结论:制备的DepoNTX包封率较高,粒子表面呈光滑球形,内部具有非同心的多囊泡结构。 Objective:To prepare the naltrexone hydrochloride multivesicular liposomes(DepoNTX),and study its physicochemical properties.Methods:DepoNTX were prepared using multiple emulsion method.RP-HPLC was used to determine the concentration of naltrexone and encapsulation efficiency.The formulation and pharmaceutical process were optimized by single factor design and orthogonal experimental design with the encapsulation efficiency as the criteria.The multivesicular liposomes particles were characterized by their morphology which was observed using light microscope,the particle size and distribution were determined by coulter counter.Results:The optimal formula was as follows:the mole ratio of phosphatidylcholine to cholesterol was 1:1,the vortex time for emulsion polymerization was 10 s,the concentration of L-lysine was 40 mmol·L-1,the volume ratio of the first emulsification to the second aqueous phase solution was 1:2.5.The particle sizes of DepoNTX were 5-50 μm with the mean particle size of 12.4 μm,the encapsulation efficiency of DepoNTX was 44.5%.Conclusion:DepoNTX was successfully encapsulated in this depot with high yield,and showed spherical shape with the non-concentric multivesicular aqueous compartment.
出处 《中国药物应用与监测》 CAS 2010年第6期338-341,共4页 Chinese Journal of Drug Application and Monitoring
关键词 纳曲酮 多囊脂质体 包封率 制备工艺 Naltrexone Multivesicular liposomes Encapsulation efficiency Preparation technology
  • 相关文献

参考文献15

  • 1Tucker TK,Ritter AJ.Naltrexone in the treatment of heroin dependence:a literature review[J].Drug Alcohol Rev,2000,19(1):73-82.
  • 2Rossi S,Sandri G,Cararnella CM,et al.Buccal drug delivery:a challenge already won[J].Drug Discov Today,2005,2(1):59-65.
  • 3Thomas CP,Wallack SS,Lee S,et al.Research to practice:adoption of naltrexone in alcoholism treatment[J].J Subst Abuse Treat,2003,24(1):1-11.
  • 4Giannola LI,De Caro V,Gtandalia G,et al.Release of naltrexone on buccal mucosa:permeation studies,histological aspects and matrix system design[J].Eur J Pharm Biopharm,2007,67(2):425-433.
  • 5Yin W,Akala EO,Taylor RE.Design of naltrexone loaded hydrolysable crosslinked nanoparticles[J].Int J Pharm,2002,2440-21:9-19.
  • 6Valiveti S,Paudel KS,Hammell DC,et al.In vitro/in vivo correlation of transdcrmal naltrexone prodrugs in hairless guinea pigs[J].Pharm Res,2005,22(6):981-989.
  • 7Valiveti S,Hammell DC,Paudel KS,et al.In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs[J].J Control Release,2005,102(2):509-520.
  • 8Kim S,Turker MS,Chi EY,et al.Preparation of multivesicular liposomes[J].Biochim Biophys Acta,1983,728(3):339-348.
  • 9王晓梅,唐星,何海冰.多囊脂质体的研究进展[J].中国新药杂志,2006,15(15):1243-1246. 被引量:17
  • 10Ye Q,Asherman J,Stevenson M,et al.DepoFoam technology:a vehicle for controlled delivery of protein and peptide drugs[J].J Control Release,2000,64(1-3):155-166.

二级参考文献41

  • 1KIM S, TURKER M S, CHI E Y, et al. Preparation of multivesicular liposomes[ J]. Biochim Biophys Acta, 1983,728 (3) :339 -348.
  • 2ZHONG Hai-jun, DENG Ying-jie, WANG Xiu-min, et al. Multivesicular liposome formulation for the sustained delivery of breviscapine[ J]. Int J Pharm,2005, 301(1/2) :15 -24.
  • 3KIM S, HOWELL S B. Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride: US ,5807572 [ P]. 1998 - 09 - 15.
  • 4KATRE N V, ASHERMAN J, SCHAEFER H, et al. Multivesicular liposome (DepoFoam) technology for the sustained delivery of insulin-like growth factor-Ⅰ (IGF-Ⅰ) [ J]. J Pharm Sci, 1998,87 ( 11 ) : 1341 - 1346.
  • 5HARTOUNIAN H,MEISSNER D ,PEPPER C B. Production of multivesicular liposomes: US,20020039596 [ P].2002 - 04 - 04.
  • 6ELLENA J F,LE M,CAFISO D S,et al. Distribution of phospholipids and triglycerides in multivesicular lipid particles [ J ]. Drug Deliv, 1999,6 (2) :97 - 106.
  • 7MANTRIPRAGADA S. A lipid based depot (Depo- Foam^ technology) for sustained release drug delivery [ J ]. Prog Lipid Res, 2002,41 ( 5 ) : 392 - 406.
  • 8WILLIS R S. Method for utilizing neutral lipids to modiey in vivo release from multivesicular liposomes: US ,5891467 [ P]. 1999 - 04 - 06.
  • 9Gonser s,Weber E,Folkers G.Peptides and polypeptides as modulatom of the immune response:thymopentin an example with unknown mode of action[J].Pharma Acta Helve,1999,73(6):265-273.
  • 10Tischio JP,Patrick JE,Weintraub HS,et al.Short in vitro halflife of Thymopoietin32-36 pentapeptide in human plasma[J].Int J Peptide Protein Res,1979,14:479-484.

共引文献24

同被引文献7

  • 1Shen Y, Ji Y,Xu al. Multi vesicular liposome formulations for thesustained delivery of ropivacaine hydrochloride : Preparation,,charac-terization ,,and pharmacokinetics[ J]. Drug Deliv,201A ,18(5) :361-366.
  • 2Lei L,Wei Z,Xin W,et al. A novel ropivacaine-loaded in situ form-ing implantprolongs the effect of local analgesia in rats[ J] . Arch MedSci’ 2013,9(4) :614-621.
  • 3Kim S, Sankaram MB. Multivesicular liposomes with controlled releaseof encapsulated biologically active substances [ P]. US; 6132766.2000-10-17.
  • 4Zuo J,Gong T,Sun X,et al. Multivesicular liposomes for the sustainedrelease of thymopentin : stability, pharmacokinetics and pharmacody-namics[ J]. Pharmazie,2012,67(6) :507-512.
  • 5陶昱斐,姚瑶,丁燕飞,陈若飞,肖灿.酪丝亮肽多囊脂质体的制备和体外释放研究[J].中国新药杂志,2008,17(3):228-232. 被引量:9
  • 6郭冰.盐酸罗哌卡因在体成形微粒的制备与质量测定[J].抗感染药学,2012,9(1):47-49. 被引量:1
  • 7毛小明.粉防己碱醇质体含量及包封率测定[J].中国药师,2013,16(10):1529-1531. 被引量:1

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部